Treace Medical Concepts (TMCI) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1-year price targets for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $25.00 to $30.00. On average, they predict the company's stock price to reach $28.13 in the next year. This suggests a possible upside of 113.7% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.

Treace Medical Concepts' stock was trading at $22.99 on January 1st, 2023. Since then, TMCI shares have decreased by 42.8% and is now trading at $13.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our TMCI earnings forecast.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The company had revenue of $41.95 million for the quarter, compared to the consensus estimate of $40.84 million. Treace Medical Concepts had a negative net margin of 25.32% and a negative trailing twelve-month return on equity of 39.29%. The business's revenue for the quarter was up 40.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.23) earnings per share.

Treace Medical Concepts updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $191.00 million-$197.00 million, compared to the consensus revenue estimate of $194.06 million.

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

Treace Medical Concepts' stock is owned by a variety of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (5.56%), BlackRock Inc. (5.09%), Perceptive Advisors LLC (3.60%), Driehaus Capital Management LLC (2.40%), Point72 Asset Management L.P. (2.30%) and State Street Corp (1.88%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends.

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMCI stock can currently be purchased for approximately $13.16.

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $809.87 million and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

The company employs 423 workers across the globe.

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.